zh-twzhen
zh-twzhen

NEWS

合一生技股份有限公司 / 2022 / Oneness Biotech Co.,LTD receives a China patent on antagonistic PDL1 aptamers.

Oneness Biotech Co.,LTD receives a China patent on antagonistic PDL1 aptamers.

2022-05-26

Published Date:2022-05-26

Original Link:https://www.onenessbio.com/en/news_detail168_2.htm

No 1 Date of announcement 2022/05/26 Time of announcement 16:41:48
Subject Oneness Biotech Co.,LTD receives a China patent on antagonistic PDL1 aptamers.
To which item it meets paragraph 53 Date of events 2022/05/26
Statement
  1. Date of occurrence of the event:2022/05/26
  2. Company name:ONENESS BIOTECH CO., LTD.
  3. Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office
  4. Reciprocal shareholding ratios:NA
  5. Cause of occurrence:The Company has been informed by the patent agency that the antagonistic PDL1 aptamer has been granted a China patent titled ”ANTAGONISTIC PDL1 APTAMERS AND THEIR APPLICATIONS IN CANCER THERAPY” under patent number 4620171.
  6. Countermeasures:None
  7. Any other matters that need to be specified:
    (1)This patent covers the aptamers that bind to and antagonize PDL1 and uses thereof in enhancing immune activity(e.g.,promoting T cell proliferation), treating cancer, and/or infectious diseases such as infections caused by enterovirus, HBV or HCV.
    (2)This patent is owned by National Taiwan University and Academia Sinica. Oneness Biotech Co.,LTD has been exclusively authorized to use this patent and to manufacture, use and sell the products of this invention.